Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2019 16:53 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 25, 2019 08:02 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell...
February 25, 2019 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell...
February 21, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Proposes New Members to the Board of Directors

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 19, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative...
January 22, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

CAMBRIDGE, Mass. and BOSTON and BERLIN, Jan. 22, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
January 04, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the...
November 21, 2018 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 09, 2018 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology-- ZUG, Switzerland and CAMBRIDGE, Mass. and...
November 07, 2018 16:33 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

-Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting CD19+ Malignancies, in 1H 2019--$487.3 Million in Cash as of September 30,...